Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARADIGM CORP. ARDM -- Ignore unavailable to you. Want to Upgrade?

To: EVENT HORIZON III who wrote (151)	5/13/2003 9:43:31 AM
From: tuck	Respond to of 255

>>HAYWARD, Calif., May 13 /PRNewswire-FirstCall/ -- Aradigm Corporation (Nasdaq: ARDM - News), a leader in pulmonary drug delivery, announced today that it has acquired selected assets of Weston Medical, ("Weston"), a publicly held, UK-based company founded in 1994. Weston's proprietary technology, Intraject®, offers a needle-free alternative to conventional injections that has attracted commercial and development partners seeking to deliver a variety of liquid formulations. Intraject is currently in development to deliver biotherapeutics including monoclonal antibodies, proteins and small molecule drugs. The addition of the Intraject technology expands Aradigm's platform of liquid delivery alternatives, and increases its partnered portfolio by two commercial agreements and several earlier-stage development agreements. The total cost of the asset acquisition to Aradigm is approximately $2 million in cash, and includes test and production equipment, intellectual property and other assets. Weston's commercial agreements covered the Intraject delivery of PEGASYS® (PEG-interferon alpha 2-a) with Roche for hepatitis-C, Imitrex® (sumatriptan) with GlaxoSmithKline for migraine, as well as an option agreement for undisclosed products with Abbott Laboratories. "Aradigm has already developed the AERx® system, which represents the future of administering liquid formulations through pulmonary delivery. The addition of the Intraject technology further positions Aradigm as the leader in needle-free delivery" commented Richard P. Thompson, Aradigm Chairman, President and CEO. "We look forward to solidifying the current license arrangements and expanding to new applications as quickly as possible." In September 2002, Weston announced a delay in the development of Intraject that resulted in the loss of more than 95% of its $150 million market capitalization, and led to the company entering bankruptcy administration in February 2003. Laboratory and clinical evaluation of Intraject completed since September indicates that the technical problem can be resolved within the existing design parameters. Continuation of the development effort will now be managed at Aradigm in Hayward, California. After completion of the technology transfer from Weston, operations in the UK will be discontinued. Intraject is a single-use, pen-sized system that delivers liquid drugs to subcutaneous tissue. Intraject is comfortable and easy to use; in clinical trials, patients overwhelmingly preferred Intraject to a standard needle and syringe. In addition, Intraject avoids potential dosing errors from transferring solutions into syringes, and eliminates the risk of needle-stick injuries. Studies in humans have demonstrated equivalent pharmacokinetic and/or pharmacodynamic performance between subcutaneous needle injection and Intraject. According to Jean-Marie Kindbeiter, Project Leader of the Intraject PEGASYS team at Roche: "Roche views Needle Free Device (NFD) technology as a major advance in the administration of parenteral drugs, and plans to continue the collaboration with Aradigm and their Intraject technology." "Adding the Intraject project to Aradigm's portfolio extends and leverages Aradigm's core competencies," states Dr. Stephen Farr, Aradigm Chief Scientific Officer. "The technology behind AERx®, Aradigm's aerosol pulmonary drug delivery system, and Intraject, is very similar. In both cases liquid formulations are delivered under pressure through controlled nozzles. Both involve aseptically filled, single-use drug/device combinations to optimize delivery. In addition, the systems integration capabilities and quality control processes required to commercialize Intraject products are already in place at Aradigm. Given that Aradigm is proceeding through Phase 3 clinical trials with our pulmonary insulin product, we are confident that we can add significant value to defining and implementing robust and reproducible processes for Intraject." Mr. Thompson added: "The acquisition of the Intraject technology allows us to leverage our leadership in liquid pulmonary drug delivery into new areas. The explosive growth of monoclonal antibodies and PEGylated therapeutic proteins in clinical development is a key example for which we can now offer needle-free systemic delivery. At the same time, the pulmonary route has important cost and titration advantages for products that require frequent, chronic dosing. By offering both approaches to partners, we can help drive a revolution that will eliminate needle-based administration of outpatient therapies." Aradigm will continue development of Intraject by re-allocating existing resources and is anticipating no more than a small increase in its current cash burn rate. Weston had pursued a virtual manufacturing strategy with key manufacturing activities performed at the facilities of several contract manufacturing organizations (CMOs). Many of these existing CMO relationships can be reestablished in order to minimize internal resource requirements, while infrastructure such as Quality will be leveraged across both AERx and Intraject projects. According to Tom Chesterman, Aradigm Chief Financial Officer: "Attaining key technical and business milestones, with judicious resource allocations to both Intraject and AERx over the next three to four quarters, will be important for building Aradigm's long-term value." Conference Call Aradigm will discuss details of the asset acquisition in a conference call today at 1:30 pm Eastern Time, 10:30 am Pacific Time. Dial toll-free 1-866-541-2081 to access the call. International callers dial +1-630-424-2081. The event webcast can be found under the investor relations section of: www.aradigm.com. The webcast and audio replay of the conference call will be available following the call, which can be accessed on www.aradigm.com or by dialing toll-free 1-888-843-8996. International callers should dial +1-630-424-2081. The replay passcode is 7191022.<< snip Cheers, Tuck

To: EVENT HORIZON III who wrote (151)	8/13/2003 10:25:13 PM
From: Tadsamillionaire	Respond to of 255

.In addition to the diabetes, morphine and fentanyl programs, we have four additional AERx programs in development, three of which are partner funded. 2.Contract revenues consist of revenue from collaboration agreements and feasibility studies 3Contract and License Revenues: Contract revenues for the three months ended June 30, 2003 increased to $9.4 million from $7.3 million for the same period in 2002. Revenue from Novo Nordisk was $9.3 million for the three months ended June 30, 2003 and $6.6 million for the same period in 2002. The increase in revenue is related to increased reimbursement by Novo Nordisk for clinical supply and product development activities for the ongoing phase 3 clinical program and offset by lower revenue from other funded programs. 4Our next program has been conducted to date with our partner GlaxoSmithKline pursuant to our development agreement, as amended, which covers the use of the AERx Pain Management System for the delivery of narcotic analgesics. Activity in this program has been limited since delivery to GlaxoSmithKline of data from the Phase 2b clinical trials in the second quarter of 2002. We are in a position to move forward with this program and start Phase 3 trials within a year; however, future progress for this program is contingent on either GlaxoSmithKline recommitting to this program or our entering into another development agreement with a new partner. 5.We have four additional programs, three of which are partner-funded programs, including two gene therapy programs. Future research and development efforts for these partner-funded programs are difficult to predict at this time due to their early stage of development. 6.On May 12, 2003, we completed the purchase of certain assets from Weston, a UK public company currently in bankruptcy. Weston’s business involved the design, development, manufacture and exploitation of drug delivery technologies, including a proprietary needle-free injection technology known as “Intraject.” We acquired test and production equipment, intellectual property and other assets associated with Weston’s drug delivery technologies for a cash consideration of $2.0 million. The acquisition was funded out of our working capital. FROM 10Q